GMP-Compliant iPS Cell Lines Show Widespread Plasticity in a New Set of Differentiation Workflows for Cell Replacement And Cancer Immunotherapy
Summary: This article discusses the development and establishment of Good Manufacturing Practice (GMP) compliant workflows for generating induced pluripotent stem cell (iPSC) lines and their differentiated progeny for cell therapeutic applications. It highlights the stringent quality and consistency requirements imposed by GMP regulations and presents newly developed protocols for the production and differentiation of these iPSC lines into various critical cell types. The article also introduces an innovative platform for inducing immune cells from iPSCs.